Board of Directors

Susan Gallagher

Susan Gallagher established a successful track record as a principal investor at Chase Manhattan Bank, Allied Capital Corporation and Thayer Capital Partners before founding Williams & Gallagher, LLC in 2004 in partnership with Cabell Williams. Ms. Gallagher was a Partner at Thayer Capital Partners, a Washington-based private equity investment firm from 1996 to 2000. The firm raised over $1.2 billion and invested in 18 growing companies during her tenure. As a Partner and one of four members of the firm's Investment Committee, Ms. Gallagher was responsible for reviewing and approving all of the firm's investment and divestiture decisions. Prior to joining Thayer, Ms. Gallagher was a Vice President at Allied Capital Corporation from 1992 to 1996. At Allied, Ms. Gallagher originated seven mezzanine and private equity investments in media, retail, and business services companies which generated an average internal rate of return of over 23%. Prior to Allied, Ms. Gallagher worked as a credit policy analyst and a commercial loan officer for Chase Manhattan, now JP Morgan Chase in New York. Ms. Gallagher received her Master of Business Administration degree from Harvard Business School and a Bachelor of Arts from Wellesley College. Ms. Gallagher currently serves on the Board of Directors of Tales2Go, a privately held audio book education company, and Molecular Transfer, Inc., a private company that discovers and manufactures stem cells and reagents used in biology research. She also serves on the Board of Trustees of St. George’s School in Newport, RI.

David M. Manyak, Ph.D

David Manyak has been involved in the biotechnology or life sciences industry for the past 35 years in both finance and executive management capacities.  He started his career as a securities analyst, first with Value Line Inc., then as V.P. & Senior Biotechnology Industry Analyst at Merrill Lynch & Co., where he initiated coverage of biotechnology stocks and was involved in corporate finance transactions.  Dr. Manyak was a co-founder of a number of life sciences companies, including GeneMedicine Inc., a gene therapy company, and NovaScreen Biosciences Corp., a leader in providing drug discovery and preclinical pharmacological testing services.   He served as President/CEO and Chairman of NovaScreen from 1993-2005, at which time the company was acquired by Caliper Life Sciences, a public life sciences tools company.  Dr. Manyak remained at Caliper as Executive V.P., running its drug discovery services business unit until Caliper was merged into PerkinElmer Inc. in 2011.  Since then, he has served as an advisor to, and investor in, a number of life sciences companies, and is a member of the Board of Directors of Molecular Transfer Inc. and of a family-owned oyster aquaculture business, Sapidus Farms Inc.  Dr. Manyak graduated from Brown University with a B.A. in Marine Sciences and received his Ph.D. in Zoology/Biochemistry from Duke University.

Bill Snider

Bill Snider is co-founder and Managing Partner at BroadOak. Mr. Snider has over 20 years of institutional investment experience. Prior to BroadOak, he was a general partner and co-founder of Emerging Technology Partners, LLC, a life sciences focused venture capital firm. He invested in over 20 life science companies while at ETP of which more than half were or are now publicly traded. Mr. Snider, at various times, acted as lead investor, board member and chairman for ETP’s portfolio companies. Prior to ETP he was a vice president and portfolio manager at T. Rowe Price. His responsibilities included managing $2 billion of mutual fund and institutional client portfolios. Some of Mr. Snider’s past directorships include Alpha Innotech and Atto Biosciences and he currently serves on the boards of Molecular Transfer and the MdBio Foundation.

Bill holds the Chartered Financial Analyst accreditation, a B.S. in Finance and an M.B.A. from the Wharton School at the University of Pennsylvania.

John Thompson

John Thompson has served as a consultant and board member to a number of life sciences enterprises. Previously, he was Senior Vice President, Strategy and Corporate Development at Invitrogen Corporation, where he completed over 20 transactions with an aggregate value in excess of $2 billion, in-licensed more than 200 compounds, and charted the company’s ambitious growth plans. Previously he was Senior Vice President, Strategic and Business Development at Dexter Corporation, where he led restructuring activities involving more than a dozen acquisitions and divestitures. Earlier he was Vice President, Financial Services and Treasurer, where he negotiated financings totaling $100 million, and refinanced multi-currency debt and credit agreements.Mr. Thompson also worked at Dexter subsidiary, Life Technologies. As Senior Vice President and General Manager, Americas Research Products Division, he helped achieve annual double-digit sales and earnings growth while divesting less promising businesses. As Vice President Finance, Secretary and Treasurer, he helped focus the business on high technology products, oversaw the merger that resulted in the formation of Life Technologies and helped ensure the success of its IPO. Mr. Thompson began his career in public accounting at Ernst & Young. He received a BBS degree from Cleveland State University. 

Derek E. Woods, Ph.D.

Derek Woods has more than 20 years of experience in the Pharmaceutical and Life Sciences industries. Prior to retiring in 2006, he served as Chief Executive Officer and President of Atto Biosciences and after the acquisition by Becton, Dickinson and Company (BD) in 2004, as Executive Vice President at BD. From 1996 to 2001 Derek was Vice President of Research and Development and Corporate Development at Life Technologies Inc. and an Officer of the company. Prior to joining Life Technologies Inc., Derek worked for Johnson & Johnson for 14 years in various Research and Business Development positions. Before joining J&J Derek was an assistant Professor at Harvard Medical School. He currently serves on the boards of Molecular Transfer, Inc., and Adlyfe, Inc.. Derek received a B.S. in in Biochemistry and Microbiology and a Ph.D. in Molecular biology from the University of Cape Town.

There are no products to list in this category.